← FDA DRUG APPROVALS

FDA ANDA · ANDA217559

THIOTEPA

Sponsor: REGCON HOLDINGS

APPLICATION
ANDA217559
TYPE
ANDA
ORIGINAL APPROVAL
2024-08-20
LATEST ACTION
2024-08-20
ROUTE
INTRACAVITARY, INTRAVENOUS, INTRAVESICAL
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

THIOTEPAPrescription
THIOTEPA 15MG/VIAL · POWDER · INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

Approval history

2024-08-20UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →